The complex field of pharmacokinetics relates the bloodstream concentration to the ingested amount over time. The simple version uses a "volume of distribution" which, for salicylate, is 11.9 liters for a standard male. [https://sepia.unil.ch/pharmacology/index.php?id=83].
So to achieve the 1 - 7 milimolar concentrations they used would require 3.8 - 27.2 grams of aspirin.
It seems like this might merit further research as a treatment for severe cases, but it's far too dangerous to be a prophylactic for healthy people.
(And that's all assuming these results on other coronaviruses apply to the new coronavirus that causes COVID-19.)
Drugs don't evenly distribute in the body. Some drugs get bound to specific proteins, so the observed concentration is much lower (i.e. higher volume of distribution). Others get concentrated in specific organs once they equilibrate across the body.
> The results indicate an effective concentration 50 (EC50) of 1.31 mM for HCoV-229E resulting in a selectivity index (SI: CC50/IC50) of 15.6 as well as an EC50 of 3.69 mM for MERS-CoV, leading to an SI of 15.9, similar to that of HCoV-229E (Figures 2D and 2E). The EC50 for HCoV-229E-infected PBMCs at 24 h was 6.71 mM resulting in an SI of 5.7 (Figure 2F).
And if tlb is right that the volume of distribution is under 12 liters, the dose required in the best case would be approximately the maximum dose of aspirin (4 grams). In the worst case, far more.
The average volume of a human is around 62 liters.
The effective concentration for the highest EC50 is 6.71mM. The lowest EC50 is 1.31.
Aspirin DL-lysine as a molecular weight of 326.34.
Therefore, to reach the concentrations used in the study, the average person would have to consume somewhere between 26 and 135g of asprin (from the two molarities above). Way above the maximum safe daily dose, which is 4 grams.
Using the absolute best case scenario- 1.31mM- and an effective volume of 12 liters, that's still 5.1g. Which is /just/ under the max safe dose. At 6.71mM, that's 26g.